Crizotinib Exhibits Antitumor Activity by Targeting ALK Signaling not c-MET in Pancreatic Cancer

Crizotinib, a c-MET/ALK inhibitor, has exhibited antitumor efficacy in different types of cancers. However, studies regarding Crizotinib in pancreatic cancer have been limited. Thus, we investigated the effect of Crizotinib on pancreatic cancer and its mechanism of action. Crizotinib strongly suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hong Hua, Jung, Kyung Hee, Son, Mi Kwon, Fang, Zhenghuan, Kim, Soo Jung, Ryu, Ye-Lim, Kim, Juyoung, Kim, Mi-Hyun, Hong, Soon-Sun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253425/
https://www.ncbi.nlm.nih.gov/pubmed/25193856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4253425/
https://www.ncbi.nlm.nih.gov/pubmed/25193856

Ejemplares similares